促销时间表 Reneo Pharmaceuticals, Inc.
先进的时间表
简单图表
关于公司 Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.| IPO date | 2021-04-08 |
|---|---|
| ISIN | US75974E1038 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://reneopharma.com |
| Цена ао | 1.65 |
| 每日价格变化: | 0% (1.82) |
|---|---|
| 每周价格变化: | 0% (1.82) |
| 每月价格变化: | 0% (1.82) |
| 3个月内价格变化: | +9.64% (1.66) |
| 六个月内的价格变化: | +20.53% (1.51) |
| 每年价格变化: | +13.75% (1.6) |
| 3年内价格变化: | -73.55% (6.88) |
| 5年内价格变化: | 0% (1.82) |
| 10年价格变化: | 0% (1.82) |
| 年初以来价格变化: | 0% (1.82) |
|
|
低估
|
效率
|
|||||||||||||||||||||||||||||||||||||
股息
|
责任
|
成长冲动
|
|||||||||||||||||||||||||||||||||||||
| 机构 | 体积 | 分享, % |
|---|---|---|
| NEA Management Company, LLC | 4785494 | 14.32 |
| Tang Capital Management, LLC | 3330000 | 9.96 |
| Carlyle Group Inc. | 2698957 | 8.08 |
| RiverVest Venture Management LLC | 2534220 | 7.58 |
| Octagon Capital Advisors LP | 2250000 | 6.73 |
| Bml Capital Management, LLC | 1314229 | 3.93 |
| Highbridge Capital Management, LLC. | 1121704 | 3.36 |
| Blackrock Inc. | 983304 | 2.94 |
| Vanguard Group Inc | 978889 | 2.93 |
| Aisling Capital Management LP | 886075 | 2.65 |
| ETF | 分享, % | 本年盈利能力, % | 股息, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.00768 | 17.09 | 1.54048 |
| Principal Healthcare Innovators ETF | 0.00594 | 618.5 | 0.8416 |
| Future Tech ETF | 0.00594 | 426.34 | 0.8416 |
| Invesco Nasdaq Biotechnology ETF | 0.00486 | 28.58 | 0.8565 |
| ProShares Ultra Nasdaq Biotechnology | 0.00333 | 51.7 | 0.85651 |
| 导师 | 职称 | 支付 | 出生年份 |
|---|---|---|---|
| Mr. Michael G. Grey | Founder & Executive Chairman | 100k | 1953 (72 年) |
| Mr. Gregory J. Flesher | President, CEO & Director | 569.7k | 1970 (55 年) |
| Mr. Michael P. Cruse | Chief Operating Officer | 535.47k | 1972 (53 年) |
| Ms. Jennifer P. Lam | SVP of Finance & Administration and Principal Financial & Accounting Officer | N/A | |
| Dr. Alejandro Dorenbaum M.D. | Chief Medical Officer | 466.23k | 1961 (64 年) |
地址: United States, Irvine. CA, 18575 Jamboree Road - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://reneopharma.com
网站: https://reneopharma.com
